Affimed N.V. (AFMD) surged 68.5% after the company reported follow-up efficacy data from the EGFR wild- type (EGFRwt) cohort and initial clinical efficacy data from the EGFR mutant (EGFRmut) cohort of the ongoing early to mid-stage study of AFM24 to treat non-small cell lung cancer (NSCLC) patients. The phase I/IIa AFM24-102 study is evaluating AFM24 in combination with Roche’s (RHHBY) immuno- oncology drug, Tecentriq (atezolizumab), in heavily pre-treated NSCLC patients. Please note that the company first ...